Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Schedule 1 Part 2 12.: Difference between revisions
From GxPlex
Gxplex admin (talk | contribs) m 1 revision imported |
gxplex>GxPlexBot Import from GxPlex Excel |
||
| Line 11: | Line 11: | ||
}} | }} | ||
{{:Document:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004}} | {{:Document:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004}} | ||
{| class="gplx-infobox" | |||
{| class=" | |||
|- | |- | ||
! | ! colspan="2" class="gplx-infobox-header" | Reference Details | ||
|- | |||
! Scope | |||
| HM | | HM | ||
|- | |- | ||
! | ! Document part | ||
| Schedule 1 | | Schedule 1 | ||
Part 2 | Part 2 | ||
12. | 12. | ||
|- | |- | ||
! | ! Language | ||
| EN | | EN | ||
|- | |- | ||
! | ! Original entry by | ||
| Florian Adragna | | Florian Adragna | ||
|- | |- | ||
! | ! Contributors | ||
| Â | | Â | ||
|- | |- | ||
! | ! Tags (EN) | ||
| Â | | Â | ||
|- | |- | ||
! | ! Tags (original language) | ||
| Â | | Â | ||
|- | |- | ||
! | ! Tags (FR) | ||
| Â | | Â | ||
|- | |- | ||
! | ! Comment | ||
| GCP principles: responsibilities for IMP management | | GCP principles: responsibilities for IMP management | ||
|} | |} | ||
== | == Content == | ||
CONDITIONS AND PRINCIPLES WHICH APPLY TO ALL CLINICAL TRIALS | CONDITIONS AND PRINCIPLES WHICH APPLY TO ALL CLINICAL TRIALS | ||
Principles based on International Conference on Harmonisation GCP Guideline | Principles based on International Conference on Harmonisation GCP Guideline | ||
Revision as of 14:27, 29 June 2026
| Document information | |
|---|---|
| Reference | GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 |
| Validity area | GBR |
| Scope(s) | HM |
| Document name | The Medicines for Human Use (Clinical Trials) Regulations 2004 |
| Version / Revision | 01-May-2004 |
| Status | Current |
| Document type | Legal act |
| Language(s) | EN |
| Description | The Medicines for Human Use (Clinical Trials) Regulations 2004 |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
| Reference Details | |
|---|---|
| Scope | HM |
| Document part | Schedule 1
Part 2 12. |
| Language | EN |
| Original entry by | Florian Adragna |
| Contributors | |
| Tags (EN) | |
| Tags (original language) | |
| Tags (FR) | |
| Comment | GCP principles: responsibilities for IMP management |
Content
CONDITIONS AND PRINCIPLES WHICH APPLY TO ALL CLINICAL TRIALS Principles based on International Conference on Harmonisation GCP Guideline [...] 12. Investigational medicinal products used in the trial shall be— (a)manufactured or imported, and handled and stored, in accordance with the principles and guidelines of good manufacturing practice, and (b)used in accordance with the approved protocol.
